Why is Vivo Bio Tech falling/rising?

As of 10-Jul, Vivo Bio Tech Ltd. is currently priced at 35.62, reflecting a slight increase of 0.12 or 0.34%. The stock has shown a trend reversal, gaining after four consecutive days of decline. Despite this recent uptick, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has underperformed the benchmark Sensex, with a return of -3.99% compared to the Sensex's -0.06%. However, there has been a notable increase in investor participation, with delivery volume rising by 161.47% against the 5-day average. While the stock has generated a negative return of -5.77% over the past year, it has seen a significant profit increase of 187.8%, contributing to its attractive valuation despite a decrease in promoter holding to 39.06%.
In the broader market context, Vivo Bio Tech's recent performance contrasts with the Sensex, which has gained 0.97% over the past month. The stock's long-term fundamentals appear weak, with a -3.36% CAGR growth in net sales over the last five years and a low return on equity of 7.52%. These factors, combined with the company's poor EBIT to interest ratio and flat results in March 2025, suggest challenges in profitability and debt servicing. Consequently, while the stock has experienced a minor rise today, its overall performance remains concerning in the context of both short-term and long-term metrics.